FDA issues warnings over misleading compounded weight-loss drug ads
The agency targeted advertising claims for compounded versions of obesity medicines, according to the report.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 11 20:21 ETSource: Olhar Digital
The wire
- 01The report says FDA issued warnings aimed at misleading advertising for compounded weight-loss drugs.
- 02Compounders and telehealth sellers marketing compounded GLP-1 products are the obvious audience for any enforcement on promotional claims.
- 03Details of which firms were warned, the specific claims cited and any required corrective action are not given in the item.
From the source
Read at olhardigital.com.brthe fda issued warnings for misleading compounded weight-loss drug ads
